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INTRODUCTION
The frequency of breast reconstruction after mastectomy for 
breast cancer has increased. Immediate breast reconstruction 
(IBR) is associated with improved psychosocial recovery, espe-
cially when performed at the time of the mastectomy [1-3].     
A study has demonstrated the benefits of IBR, which include 
improved psychological and aesthetic outcomes [4]. 
Adjuvant chemotherapy is a life-saving intervention in selected 
high-risk breast cancer patients. According to current guide-
lines, chemotherapy should be initiated within 4-12 weeks after 
surgery [5,6]. Previous reports have shown that survival does 
not diﬀer among patients of whom chemotherapy was initiated 
within 1, 2, or 3 months after surgery. Delay beyond 3 months 
was, however, associated with increased disease-specific mor-
tality and overall mortality [7,8]. One barrier to the use of IBR 
is the concern that the complications of immediate reconstruc-
tion may delay wound healing and initiation of adjuvant che-
motherapy [9]. Several studies have been carried out of the 
potential delay of adjuvant treatment after IBR. However, vari-
ous publications have also demonstrated that IBR is safe and 
does not delay the start of adjuvant chemotherapy [4,10]. 
Various types of reconstruction may be performed after 
mastectomy, but little is known about the impact of the type 
of IBR on the administration of adjuvant chemotherapy. To 
determine whether the timing of chemotherapy is aﬀected by 
immediate reconstruction and the type of IBR, we performed 
a retrospective study of patients.
METHODS
We obtained data from female breast cancer patients treated 
by mastectomy with IBR (IBR group) and without IBR (mastec-
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Purpose: The frequency of immediate breast reconstruction (IBR) 
is increasing, and the types of reconstruction used are diverse. 
Adjuvant chemotherapy is a life-saving intervention in selected 
high-risk breast cancer patients. The aim of our study was to   
determine how IBR and type of reconstruction affect the timing 
of the initiation of chemotherapy. Methods: We obtained data 
from female breast cancer patients treated by mastectomy with 
IBR (IBR group) and without IBR (mastectomy only group) who 
received adjuvant chemotherapy between January 1, 2008, and 
December 31, 2010. We retrospectively collected data including 
patient characteristics, disease characteristics, treatment details, 
and treatment outcomes from our institutional electronic patient 
database and medical treatment records. The reconstruction types 
were categorized as deep inferior epigastric perforator (DIEP) flap, 
latissimus dorsi (LD) flap and tissue expander/implant (TEI). Results: 
In total, 595 patients were included in this study. Of these patients, 
43 underwent mastectomy with IBR (IBR group) and 552 patients 
did not undergo reconstruction (mastectomy only group). There 
was significant difference in the timing of the initiation of chemo-
therapy between the two groups (p<0.0001). There were no cases 
of delays of more than 12 weeks. In the IBR group, 20 patients 
received TEI, 9 patients were treated by the insertion DIEP flaps, 
and 14 patients were treated by LD flaps. There were no signifi-
cant differences in the timing of chemotherapy according to the 
type of reconstruction (p=0.095). Conclusion: IBR delays the ini-
tiation of chemotherapy, but does not lead to omission or signifi-
cant clinical delay in chemotherapy. Further, the type of recon-
struction does not affect the timing of chemotherapy.
Key Words: Adjuvant chemotherapy, Breast neoplasms, Breast reconstruction
Correspondence:  Jeong Eon Lee 
Division of Breast and Endocrine Surgery, Department of Surgery,  
Samsung Medical Center, Sungkyunkwan University School of Medicine,  
50 Irwon-dong, Gangnam-gu, Seoul 135-710, Korea 
Tel: +82-2-3410-0338, Fax: +82-2-3410-6982
E-mail: jeongeon.lee@samsung.com
Received: June 20, 2011  Accepted: November 4, 2011
Journal of
        Breast
CancerImmediate Breast Reconstruction (IBR) and Adjuvant Chemotherapy 323
http://dx.doi.org/10.4048/jbc.2011.14.4.322  http://ejbc.kr
tomy only group) who received adjuvant chemotherapy at the 
Samsung Medical center between January 1, 2008, and Decem-
ber 31, 2010. We retrospectively collected data including pa-
tient characteristics, disease characteristics, treatment details, 
and treatment outcomes from our institutional electronic pa-
tient database and medical treatment records. Details included 
age at diagnosis, body mass index (BMI), histopathological 
staging and tumor size, number of positive nodes, date of mas-
tectomy and immediate reconstruction, type of reconstruction, 
date of removal of drain and discharge, start of adjuvant che-
motherapy and wound complications. When the drainage fluid 
was 30 mL or less in a 24-hour period, it was removed. Patients 
were staged according to the American Joint Committee on 
Cancer (AJCC, 7th edition) categories.
All patients underwent total mastectomy (TM) of the aﬀected 
breast and ipsilateral axillary lymph node dissection (ALND) 
or sentinel lymph node (SLN) biopsy. In some cases, patients 
underwent one or more partial mastectomies (PM) before TM, 
and some had ALND or SLN biopsy at the time of a prior PM. 
In all patients of the study group, at the time of TM, IBR was 
performed by a plastic surgeon. The reconstruction types were 
categorized as deep inferior epigastric perforator (DIEP) flap, 
latissimus dorsi (LD) flap, and tissue expander/implant (TEI).  
The choice of the best flap to use for patients depends on 
many factors, including body type and breast size, and on the 
hospital and the plastic surgeon who performs the operation 
as well as on the patient. In our institution, the plastic surgeons 
explained to the patients the advantages and disadvantages of 
each type of reconstruction preoperatively, and the choice was 
then left entirely to the patient’s judgment.
In cases of TEI, expansion is normally performed 2 to 4 weeks 
after expander insertion and is continued serially 1 to 2 weeks 
apart until the desired size, at which point overexpansion is 
performed at up to 20% and continued irrespectively of che-
motherapy. The incision should be healing well before subject-
ing it to expansion. After an additional waiting period of at least 
2 months, the expander is then exchanged for a permanent 
breast implant.  
We excluded patients who did not undergo treatment at the 
Samsung Medical center, who received neoadjuvant (preoper-
ative) chemotherapy, and who delayed their own adjuvant 
therapy. Patients who participated in other studies associated 
with adjuvant chemotherapy were excluded from this analysis, 
since initiation of adjuvant therapy may have been delayed 
due to assays performed in these studies. 
Categorical data were analyzed by chi-square analysis. An 
independent-sample t-test was used to determine diﬀerences in 
age, BMI, tumor size, number of positive nodes, mean interval 
to the removal of surgical drains, time of discharge from the 
hospital and time of initiation of chemotherapy between the 
IBR group and mastectomy only group. One-way ANOVA was 
used to compare the characteristics of the three groups with 
IBR. Probability values of <0.05 were considered significant. 
Statistical analyses were performed using PASW Statistics 18.0 
software (SPSS Inc., Chicago, USA).
RESULTS
Between January 1, 2008 and December 31, 2010, 1,046       
female patients with breast cancer underwent mastectomy at 
our institution, and 683 of these patients received adjuvant 
chemotherapy. Nine patients who delayed their own adjuvant 
therapy and 79 patients who had participated in other studies 
associated with adjuvant chemotherapy were excluded. In total, 
595 patients were included in this study. Of these patients, 43 
underwent mastectomy with IBR (IBR group) and 552 patients 
did not undergo reconstruction (mastectomy only group). In 
the IBR group, 20 patients received TEI, 9 patients were treated 
by reconstruction with DIEP flaps, and 14 patients were treated 
by reconstruction with LD flaps. 
The characteristics of the two groups are summarized in 
Table 1. The patients in the mastectomy only group were older 
and more obese than those in the IBR group (p=0.0001 and 
p=0.002, respectively). The patients in the mastectomy only 
group were more likely to have larger tumors (p<0.0001), greater 
numbers of positive nodes (p<0.0001) and more advanced 
disease (p=0.004) than the patients in the IBR group. There 
were significant diﬀerences in the time intervals prior to the 
removal of surgical drains, discharge from the hospital and start 
of chemotherapy between the two groups (p<0.0001, p<0.0001, 
and p<0.0001, respectively) (Figure 1). There was a statistically 
significant diﬀerence in wound complications between the two 
groups (p<0.0001) (Table 1). 
Wound complications include wound dehiscence, infection 
and skin flap necrosis, seroma, and skin flap demarcation (Figure 
2). The most common postoperative complication is seroma 
(43.5%, 10 of 23) (Table 2). Skin flap necrosis was defined as 
full-thickness skin loss. Infectionous complications included 
both those requiring oral antibiotics and treatment in the out-
patient setting as well as those requiring hospital admissions for 
intravenous antibiotic therapy (Table 2). There were significant 
diﬀerences in the time intervals prior to removal of surgical 
drains, discharge from hospital and start of chemotherapy   
between the patients with and without wound complications 
(Table 3).
There were no cases of delay in initiation of chemotherapy 
of more than 12 weeks after surgery in the two groups. Also, in 
all patients with advanced (stage III) disease who underwent 324   Jeonghui Lee, et al.
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Table 1. Patient characteristics and clinical outcomes
Characteristics
IBR group  
(n=43)
Mastectomy only 
group (n=552)
p-value
Age (yr) 43.2±7.9 48.1±9.1 0.0001
Body mass index  21.9±2.4 23.3±3.1 0.002
Tumor size (cm)   2.3±1.5   3.4±2.3 <0.0001
No. of positive node   1.1±1.3   4.1±7.0 <0.0001
Stage* 0.004
   I   9 (20.9)   90 (16.3)
   II 30 (69.8) 276 (50.5)
   III 4 (9.3) 186 (33.7)
Interval to remove 
   of drains (day)  
12.5±4.9   7.0±3.8 <0.0001
Hospital day 14.1±4.9   7.6±3.6 <0.0001
Interval to chemotherapy
   (day)  
31.5±9.6 24.9±6.5 <0.0001
Wound complication   9 (20.9) 14 (2.5) <0.0001
Values are presented as mean±SD or number (%).
IBR group=immediate breast reconstruction (IBR) group; Mastectomy only 
group=non-IBR group; SD=standard deviation.
*By the 7th edition of the American Joint Committee on Cancer (AJCC) clas-
sification. 
Table 2. Comparison of postoperative wound complications
Complications
IBR group  
(n=9)
Mastectomy  
only group  
 (n=14)
Total  
(n=23) 
Wound dehiscence 6 (66.7) 1 (7.1)   7 (30.4)
Infection 0   3 (21.4)   3 (13.0)
Skin necrosis 1 (11.1) 1 (7.1) 1 (8.7)
Seroma 1 (11.1)   9 (64.3) 10 (43.5)
Skin flap demarcation 1 (11.1) 0 1 (4.3)
Values are presented as number (%).
IBR group=immediate breast reconstruction (IBR) group; Mastectomy only 
group=non-IBR group.
Figure 1. Comparison of interval to drain removal and chemotherapy between immediate breast reconstruction (IBR) group and mastectomy only 
group. There were significant differences in time intervals prior to removal of surgical drains, start of chemotherapy between the two groups (p<0.0001, 
p<0.0001). (A) Interval to drain removal and frequency (IBR group). (B) Interval to drain removal and frequency (mastectomy only group). (C) Interval to 
chemotherapy and frequency (IBR group). (D) Interval to chemotherapy and frequency (mastectomy only group). SD=standard deviation.
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IBR, chemotherapy was started within 5 weeks of the surgery 
(range, 20-32; mean, 24.25 days). 
We performed a subset analysis to determine if the type of 
reconstruction influenced the start of chemotherapy. The char-
acteristics of the type of reconstructions are summarized in 
Table 4. There were no significant diﬀerences among the groups 
for age, BMI, or tumor size. The mean time for the removal of Immediate Breast Reconstruction (IBR) and Adjuvant Chemotherapy 325
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surgical drains for each group was as follows: DIEP flap 8.7 
days (range, 6-19 days), LD flap 14.1 days (range, 11-25 days), 
and TEI 13.2 days (range, 6-30 days). These diﬀerences were 
especially significant between patients receiving DIEP flaps 
and LD flaps (p=0.023). The mean time of discharge from the 
hospital and the start of chemotherapy for each group were as 
follows: DIEP flap 10.8 days (range, 7-20 days) and 27.1 days 
(range, 21-40 days), respectively, LD flap 14.6 days (range, 11-
25 days), and 36.1 days (range, 18-62 days), respectively, and 
TEI 15.2 days (range, 9-31 days) and 30.2 days (range, 20-52 
days), respectively. These diﬀerences were not significant (p= 
0.064, p=0.063). There were diﬀerences in the number of pos-
itive nodes and wound complications among the groups (p= 
0.034, p=0.002), but there was no significant diﬀerence in the 
timing of initiation of chemotherapy. 
DISCUSSION
Since IBR enhances psychological recovery from breast cancer 
[1-3] and seems to be oncologically safe [11,12], IBR proce-
dures have been widely implemented in oncoplastic surgical 
practice [13-16]. IBR is now established as a valuable option 
for patients undergoing mastectomy. Early fears that this tech-
nique would lead to increased rates of local recurrence or dif-
ficulty in detecting and subsequently treating recurrence have 
been dispelled by several published series [17-19]. The most 
widely used reconstruction techniques are tissue expanders 
(later substituted with a permanent implant), or pedicled or 
free flap procedures [20-22].
A number of studies have been carried out on the eﬀects of 
IBR on the time interval between surgery and the initiation     
of adjuvant chemotherapy, as a response to the suggestion that 
undue delay can compromise cancer treatment and conse-
quently, survival [9,10]. In a study that reviewed the eﬀect of 
the reconstruction methods (free TRAM and DIEP flaps on 
the time of commencement of adjuvant treatment), it was 
demonstrated that there is a delay in the administration of   
adjuvant treatment in the IBR free flap group compared to pa-
tients who did not undergo reconstruction. Patients receiving 
IBR experienced significant 2-week delays to the initiation of 
chemotherapy on average compared to the control group [23]. 
Table 4. Comparison of patient characteristics by type of reconstruction
Characteristics
DIEP flap  
(n=9)
LD flap  
(n=14)
TEI  
(n=20)
p-value
Age (yr) 45.6±9.4 45.3±4.6 40.7±8.6 0.154
Body mass index  22.5±2.2 21.3±1.6 22.1±3.0 0.472
Tumor size (cm)    2.1±0.9   2.2±2.1   2.3±1.3 0.946
No. of positive node   2.1±2.0   0.7±0.8   1.0±1.1 0.034 
(DIEP>LD)
Stage*         -
   I 2 (22.2)   4 (28.6)   3 (15.0)
   II 5 (16.6) 10 (71.4) 15 (75.0)
   III 2 (22.2) 0   2 (10.0)
Interval to remove of  
   drains (day)
  8.7±4.0 14.1±4.2 13.2±5.1 0.023 
(LD>DIEP)
Hospital day 10.8±4.2 14.6±4.3 15.2±5.1 0.064
Interval to chemo-
   therapy (day)
27.1±7.5   36.1±12.2 30.2±7.1 0.063
Wound complication 2 (22.2)   6 (42.9) 6 (5.0) 0.002
Values are presented as mean±SD or number (%).
DIEP=deep inferior epigastric perforator; LD=latissimus dorsi; TEI=tissue ex-
pander/implant; SD=standard deviation.
*By the 7th edition of the American Joint Committee on Cancer (AJCC) clas-
sification. Table 3. Comparison of characteristics with/without wound complica-
tions 
Characteristics
With wound  
complications
Without 
wound com-
plications
p-value
IBR  
group (a)  
(n=9)
mastectomy 
only group (b) 
(n=14)
IBR + 
mastectomy  
only group (c)   
(n=572)
Age (yr)   46.67±8.7 49.4±5.2 47.8±9.2  0.743
Body mass index    22.8±2.0 24.8±4.5 23.1±3.0  0.133
Interval to remove 
   of drains (day)
  15.3±5.0 15.0±9.8 7.1±3.6 <0.0001
(a, b>c)
Hospital day   16.0±5.0 14.9±7.2   7.7±3.7 <0.0001
(a, b>c)
Interval to chemo-  
   therapy (day)
  45.2±9.9   44.2±12.4  24.6±5.5 <0.0001
(a, b>c)
Values are presented as mean±SD.
IBR=immediate breast reconstruction; SD=standard deviation.
Figure 2. Postoperative wound complication after mastectomy with im-
mediate breast reconstruction. Wound demarcation occurred after latis-
simus dorsi flap reconstruction. On 42 days after operation, escharec-
tomy and bedside debridement underwent. 326   Jeonghui Lee, et al.
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Another study found that in seven of the 28 TRAM IBR pa-
tients, their postoperative chemotherapy was delayed due to 
surgical complications [24]. In a study that reviewed the im-
pact of breast reconstruction on the delivery of chemotherapy, 
IBR does not appear to lead to the omission of chemotherapy, 
but it is associated with a modest, but statistically significant, 
delay in initiating treatment [25]. In contrast, a study demon-
strated that IBR did not lead to a delay in the delivery of che-
motherapy when compared to conservation surgery or non-
reconstructive mastectomy [6].
In our study, the patients in the IBR group were younger than 
the patients in the mastectomy only group (p=0.0001). Other 
studies have recognized the same trend [26-28]. This likely rep-
resents patient preference, with younger patients more actively 
seeking reconstruction, as well as physician bias, with physicians 
encouraging younger patients (and less actively encouraging 
older patients) to have immediate reconstruction. Patients un-
dergoing mastectomy alone were more likely to have large     
tumors (p<0.0001), several positive nodes (p<0.0001) and 
more advanced stages of the disease (p=0.004). This probably 
reflects the fact that patients with advanced disease are required 
to be candidates for adjuvant radiation therapy, and therefore 
IBR is often not considered. Recommendations regarding IBR 
may be influenced by the likelihood that the patient will also 
require adjuvant postmastectomy chest wall and nodal radia-
tion. Reconstruction may aﬀect the technical delivery of radi-
ation, and radiation may adversely aﬀect the cosmetic results 
of reconstruction [29,30]. This concern leads some oncologists 
to recommend delayed reconstruction for women who are likely 
to receive radiation. The patients in the mastectomy only group 
were more obese than those in the IBR group (p=0.002), but 
this diﬀerence was not significantly correlated with a delay in 
the initiation of chemotherapy.
There were significant diﬀerences in the time intervals for 
the removal of surgical drains, the discharge from the hospital 
and the start of chemotherapy, and in the wound complications 
between the two groups (p<0.0001 for all factors). There was 
a correlation between the delay in initiation of chemotherapy 
and the time for the removal of surgical drains, and discharge 
from the hospital. This study examined the eﬀects of recon-
struction on the timing of the administration of chemotherapy. 
Although IBR was associated with an increased delay in chemo-
therapy initiation compared with the mastectomy only group, 
IBR did not increase the chance that adjuvant chemotherapy 
would be omitted. Some studies have found no diﬀerences in 
survival between patients given chemotherapy early, compared 
with those who received treatment up to 12 weeks postopera-
tively [7,8]. However, delays over 3 months are associated with 
diminished relapse-free survival and overall survival [7]. In our 
series, all of the breast cancer patients who received chemother-
apy started treatment within 12 weeks postoperatively. In all 
patients with advanced (stage III) disease who underwent IBR, 
chemotherapy was started within 5 weeks of the surgery. 
Another aim of this study was to determine whether the type 
of reconstruction influenced the start of chemotherapy. In one 
study, half of the patients who underwent IBR with free tissue 
transfer had their adjuvant therapy delayed by more than 40 
days. Although there were no significant diﬀerences among the 
IBR types and mastectomy alone patients, the free tissue trans-
fer subgroup did seem to have a statistically significant increase 
of 36% in the delay [6]. In this study, subgroup analysis based 
on type of reconstruction was somewhat limited due to the 
small numbers of patients in the subgroups, but no significant 
diﬀerences were found in age, BMI, or tumor size between the 
various types of reconstruction (Table 4). Meanwhile, although 
there was a significant diﬀerence in the time of the removal of 
surgical drains between the DIEP flap group and the LD flap 
group, the mean times of discharge from the hospital and start 
of chemotherapy for each group did not significantly differ. 
There were significant diﬀerences in the number of positive 
nodes and wound complications among the groups (p=0.034, 
p=0.002). The rates of wound complication were highest in the 
LD flap group and lowest in the TEI group. Although the mean 
time for the start of chemotherapy did not significantly diﬀer, 
it was longer in the LD flap group than in the other groups. 
Finally, in this study, IBR was not associated with a clinically 
significant delay or omission of adjuvant chemotherapy. How-
ever, it was associated with a statistically significant delay in 
initiating treatment. Therefore, for patients who are at higher 
risk, the additional delay associated with IBR should be con-
sidered. Our data also shows that the type of reconstruction 
does not aﬀect the delay of the initiation of chemotherapy.
This study is limited by its retrospective design and small 
number of single-center patients in each group, especially the 
study group. We also were not able to analyze all types of recon-
struction. 
There is a significant difference in the timing of initiating 
adjuvant chemotherapy after mastectomy and IBR in compar-
ison to mastectomy alone. However, IBR does not appear to 
lead to omission of chemotherapy and the diﬀerence was not 
clinically significant. Further, the type of reconstruction used 
does not aﬀect the timing of chemotherapy. 
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